Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity

Brain Research

Volumn 789, Issue 1, 1998, Pages 56-67

  Mellon, R Daniel ^a   Bayer, Barbara M ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HPA axis; Lymphocytes; Morphine; Neuroimmunology; Nociception; Opioid receptors; Rat

Indexed keywords

MORPHINE; OPIATE RECEPTOR; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ARTICLE; IMMUNE DEFICIENCY; INFECTION RISK; LYMPHOCYTE PROLIFERATION; MALE; MORPHINE ADDICTION; NATURAL KILLER CELL; NEUROIMMUNOLOGY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

EID: 0032489932     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01529-1     Document Type: Article

References (86)

1. Ader R., Cohen N., Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. The Lancet. 345:1995;99-103.
2. 3H][2-D-penicillamine, 5-D-penicillamine]-enkephalin binding to δ opiate receptors in the rat brain and neuroblastoma-glioma hybrid cell line (NG-108-15). Proc. Natl. Acad. Sci. U.S.A. 82:1985;2543-2547.
3. Bals-Kubik R., Shippenberg T.S., Herz A. Involvement of central μ and δ opioid receptors in mediating the reinforcing effects of β-endorphin in the rat. Eur. J. Pharmacol. 175:1990;63-69.
4. Band L.C., Pert A., Williams W., De Costa B.R., Rice K.C., Weber R.J. Central μ-opioid receptors mediate suppression of natural killer activity in vivo. P. NeuroEndocrinImmun. 5:1992;95-101.
5. Bartolome J.V., Chang K., Bartolome M.B. The inhibition of ornithine decarboxylase activity in developing rat tissues by central nervous system β-endorphin is mediated by μ-opioid receptors, but not by δ- or ε-opioid receptors. Eur. J. Pharmacol. 284:1995;43-50.
6. Bayer B.M., Daussin S., Hernandez M., Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology. 29:1990;369-374.
7. Bayer B.M., Gastonguay M.R., Hernandez M.C. Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility. IMPHAR. 23:1992;117-124.
8. B.M. Bayer, M. Hernandez, L. Irvin, Suppression of lymphocyte activity after acute morphine administration appears to be glucocorticoid independent, in: A. Pawloski, D. Seminara, R. Watson (Eds.), Alcohol, Immunomodulation, and AIDS, Alan R. Liss, New York, 1990, pp. 273-282.
9. Bellinger D.L., Lorton D., Romano T.D., Olschowka J.A., Felten S.Y., Felten D.L. Neuropeptide innervation of lymphoid organs. Ann. New York Acad. Sci. 594:1990;17-33.
10. Briggs F.N., Munson P.L. Studies on the mechanism of stimulation of ACTH secretion with the aid of morphine as a blocking agent. Endocrinology. 57:1955;219-260.
11. Buckingham J.C., Cooper T.A. Pharmacological characterization of opioid receptors influencing the secretion of corticotrophin releasing factor in the rat. Neuroendocrinology. 44:1986;36-40.
12. Calcagnetti D.J., Helmstetter F.J., Fanselow M.S. Analgesia produced by centrally administered DAGO, DPDPE and U50488H in the formalin test. Eur. J. Pharmacol. 153:1988;117-122.
13. Calcagnetti D.J., Holtzman S.G. Delta opioid antagonist, naltrindole, selectively blocks the analgesia induced by DPDPE but not DAGO or morphine. Pharmacol. Biochem. Behav. 38:1991;185-190.
14. Chen Z.R., Irvine R.J., Somogy A.A., Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci. 48:1991;2165-2171.
15. A.D. Corbett, S.J. Paterson, H.W. Kosterlitz, Selectivity of ligands for opioid receptors, in: A. Herz, H. Akil, E.J. Simon (Eds.), Opioids I, Springer-Verlag, New York, 1993, pp. 645-679.
16. 5]enkephalin as a highly selective ligand for the δ-binding site. Br. J. Pharmacol. 84:1985;927-932.
17. Czlonkowski A., Millan M.J., Herz A. The selective κ-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action. Eur. J. Pharmacol. 142:1987;183-184.
18. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;7479.
19. Dauge V., Petit F., Rossignol P., Roques B.P. Use of μ and δ peptides of various selectivity gives further evidence of specific involvement of μ opioid receptors in supraspinal analgesia (tail-flick test). Eur. J. Pharmacol. 141:1987;171-178.
20. Eisenberg R.M. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists. J. Pharmacol. Exp. Ther. 233:1985;863-869.
21. Eisenberg R.M. DAMGO stimulates the hypothalamo-pituitary-adrenal axis through a Mu-2 opioid receptor. J. Pharmacol. Exp. Ther. 266:1993;985-991.
22. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 276:1996;626-636.
23. Felten D.L., Felten S.Y., Carlson S.L., Olschowka J.A., Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J. Immunol. 135:1985;755s-765s.
24. Flores L.R., Dretchen K.L., Bayer B.M. Potential role of the autonomic nervous system in the immunosuppressive effects of acute morphine administration. Eur. J. Pharmacol. 318:1996;437-446.
25. Flores L.R., Hernandez M.C., Bayer B.M. Acute immunosuppressive effects of morphine: lack of involvement of pituitary and adrenal factors. J. Pharmacol. Exp. Ther. 268:1994;1129-1134.
26. Flores L.R., Wahl S.M., Bayer B.M. Mechanisms of morphine-induced immunosuppression: effects of acute morphine administration on lymphocyte trafficking. J. Pharmacol. Exp. Ther. 272:1995;1246-1251.
27. Galligan J.J., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F. Cerebral delta receptors mediate analgesia but not the intestinal motility effects of intracerebroventricularly administered opioids. J. Pharmacol. Exp. Ther. 229:1984;641-648.
28. George R., Way E.L. Studies on the mechanism of pituitary-adrenal activation by morphine. Br. J. Pharmacol. 10:1955;260-264.
29. Glaser R., Rice J., Sheridan J., Fertel R., Stout J., Speicher C., Pinsky D., Kotur M., Post A., Beck M., Kiecolt-Glaser J. Stress-related immune suppression: health implications. Brain Behav. Immun. 1:1987;7-20.
30. Gogas K.R., Levine J.D., Basbaum A.I. Differential contribution of descending controls to the antinociceptive actions of kappa and mu opioids: an analysis of formalin-evoked c-fos expression. J. Pharmacol. Exp. Ther. 276:1996;801-809.
31. Gonzalvez M.L., Milanes M.V., Vargas M.L. Effects of acute and chronic administration of μ- and δ-opioid agonists on the hypothalamic-pituitary-adrenocortical (HPA) axis in the rat. Eur. J. Pharmacol. 200:1991;155-158.
32. Gunion M.W., Rosenthal M.J., Morley J.E., Miller S., Zib B., Butler B., Moore R.D. μ-Receptor mediates elevated glucose and corticosterone after third ventricle injection of opioid peptides. Am. J. Physiol. 261:1991;R70-R81.
33. Guyla K., Pelton J.T., Hruby V.J., Yamamura H.I. Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward mu opioid receptors. Life Sci. 38:1986;2221-2229.
34. Handa B.K., Lane A.C., Lord J.A.H., Morgan B.A., Rance M.J., Smith C.F.C. Analogues of β-LPH61-64 possessing selective agonist activity at μ-opiate receptors. Eur. J. Pharmacol. 70:1981;531-540.
35. Haracz J.L., Bloom A.S., Wang R.I.H., Tseng L. Effect of intraventricular β-endorphin and morphine on hypothalamic-pituitary-adrenal activity and the release of pituitary β-endorphin. Neuroendocrinology. 33:1981;170-175.
36. 3H]CTOP), a potent and highly selective peptide for Mu opioid receptors in rat brain. J. Pharmacol. Exp. Ther. 248:1989;73-80.
37. Helmstetter F.J., Bellgowan P.S.F., Poore L.H. Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats. J. Pharmacol. Exp. Ther. 275:1995;381-388.
38. Hernandez M.C., Flores L.R., Bayer B.M. Immunosuppression by morphine is mediated by central pathways. J. Pharmacol. Exp. Ther. 267:1993;1336-1341.
39. 2] enkephalin (DPDPE). The Pharmacologist. 29:1987;106. (Abstract).
40. Hodges B.L., Gagnon M.J., Gillespie T.R., Breneisen J.R., O'Leary D.F., Hara S., Quock R.M. Antagonism of nitrous oxide antinociception in the rat hot plate test by site-specific mu and epsilon opioid receptor blockade. J. Pharmacol. Exp. Ther. 269:1994;596-600.
41. K.E. Hoffman, K.A. Maslonek, L.A. Dykstra, D.T. Lysle, Effects of central administration of morphine on immune status in Lewis and Wistar rats, in: B.M. Sharp, T.K. Eisenstein, J.J. Madden, H. Friedman (Eds.), The Brain Immune Axis and Substance Abuse, Plenum, New York, 1995, pp. 155-159.
42. Ignar D.M., Kuhn C.M. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J. Pharmacol. Exp. Ther. 255:1990;1287-1295.
43. Irwin M., Daniels M., Bloom E.T., Smith T.L., Weiner H. Life events, depressive symptoms, and immune function. Am. J. Psychiatry. 144:1987;437-441.
44. Iyengar S., Kim H.S., Wood P.L. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat. J. Pharmacol. Exp. Ther. 238:1986;429-436.
45. Iyengar S., Kim H.S., Wood P.L. μ-, δ-, κ- and ε-Opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides. Brain Res. 435:1987;220-226.
46. Jankovic B.D., Radulovic J. Enkephalins, brain and immunity: modulation of immune responses by methionine-enkephalin injected into the cerebral cavity. Int. J. Neurosci. 67:1992;241-270.
47. Keller S.E., Schleifer S.J., Liotta A.S., Bond R.N., Farhoody N., Stein M. Stress-induced alterations of immunity in hypophysectomized rats. Proc. Natl. Acad. Sci. U.S.A. 85:1988;9297-9301.
48. Keller S.E., Weiss J.M., Miller N.E., Stein M. Stress-induced suppression of immunity in adrenalectomized rats. Science. 221:1983;1301-1304.
49. Kim K.-W., Eun Y.-A., Soh S.-M., Eun J.-S., Cho K.P. Ligand binding profiles of U-69,593-sensitive and -insensitive sites in human cerebral cortex membranes: evidence of kappa opioid receptors heterogeneity. Life Sci. 58:1996;1671-1679.
50. Kiritsy-Roy J.A., Marson L., van Loon G.R. Sympathoadrenal, cardiovascular and blood gas responses to highly selective mu and delta opioid peptides. J. Pharmacol. Exp. Ther. 251:1989;1096-1103.
51. 3H]U-69593 a highly selective ligand for the opioid κ receptor. Eur. J. Pharmacol. 109:1985;281-284.
52. Levine A.S., Grace M., Billington C.J., Portoghese P.S. Nor-binaltorphimine decreases deprivation and opioid-induced feeding. Brain Res. 534:1990;60-64.
53. Locke K.W., Holtzman S.G. Behavioral effects of opioid peptides selective for mu and delta receptors: II. Locomotor activity in nondependent and morphine-dependent rats. J. Pharmacol. Exp. Ther. 238:1986;997-1003.
54. Locke K.W., Holtzman S.G. Behavioral effects of opioid peptides selective for mu or delta receptors: I. Morphine-like discrimination stimulus effects. J. Pharmacol. Exp. Ther. 238:1986;990-996.
55. Lotti V.J., Kokka N., George R. Pituitary-adrenal activation following intrahypothalamic microinjection of morphine. Neuroendocrinology. 4:1969;326-332.
56. Lysle D.T., Hoffman K.E., Dykstra L.A. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. J. Pharmacol. Exp. Ther. 277:1996;1533-1540.
57. Madden K.S., Felten D.L. Experimental basis for neural-immune interactions. Physiological Rev. 75:1995;77-106.
58. Marson L., Kiritsy-Roy J.A., van Loon G.R. μ-Opioid peptide modulation of cardiovascular and sympathoadrenal responses to stress. Am. J. Physiol. 257:1996;R901-R908. (Abstract).
59. Mellon R.D., Hernandez M.C., Flores L.R., Kellar K.J., Bayer B.M. Immunosuppression by morphine, nicotine, and epibatidine: Autonomic nervous system involvement. FASEB J. 10:1996;A129.
60. Millan M.J. Kappa-opioid receptor-mediated antinociception in the rat: I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli. J. Pharmacol. Exp. Ther. 251:1989;334-341.
61. Millan M.J. κ-Opioid receptors and analgesia. TIPS. 11:1990;70-76.
62. Millan M.J., Czlonkowski A., Lipkowski A., Herz A. Kappa-opioid receptor-mediated antinociception in the rat: II. Supraspinal in addition to spinal sites of action. J. Pharmacol. Exp. Ther. 251:1989;342-350.
63. Miller L., Shaw J.S., Whiting E.M. The contribution of intrinsic activity to the action of opioids in vitro. Br. J. Pharmacol. 87:1986;595-601.
64. Ossipov M.H., Kovelowski C.J., Nichols M.L., Hruby V.J., Porreca F. Characterization of supraspinal antinociceptive actions of opioid delta agonists in the rat. Pain. 62:1995;287-293.
65. Parrillo J.E., Fauci A.S. Mechanisms of glucocorticoid action on immune processes. Annu. Rev. Pharmacol. Toxicol. 19:1979;179-201.
66. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego, 1997.
67. Pechnick R.N. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu. Rev. Pharmacol. Toxicol. 32:1993;353-382.
68. Pfeiffer A., Herz A., Loriaux D.L., Pfeiffer D.G. Central kappa- and mu-opiate receptors mediate ACTH-release in rats. Endocrinology. 116:1985;2688-2690.
69. Portoghese P.S., Lipkowski A.W., Takemori A.E. Binaltorphimine and nor-binaltorphimine, potent and selective κ-opioid receptor antagonists. Life Sci. 40:1987;1287-1292.
70. Portoghese P.S., Sultana M., Takemori A.E. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur. J. Pharmacol. 146:1988;185-186.
71. Portughese P.S., Lipkowski A.W., Takemori A.E. Bimorphinans as highly selective, potent κ opioid receptor antagonists. J. Med. Chem. 30:1987;238-239.
72. Radulovic J., Jankovic B.D. Opposing activities of brain opioid receptors in the regulation of humoral and cell-mediated immune responses in the rat. Brain Res. 661:1994;189-195.
73. Raynor K., Kong H., Yasuda K., Bell G.I., Reisine T. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol. Pharmacol. 45:1994;330-334.
74. Schaus K., Holmes B.B., Fujimoto J.M. Differential contribution of descending serotonergic and noradrenergic systems to central Tyr-D-Ala-Gly-NMePhe-Gly-ol (DAMGO) and morphine-induced antinociception in mice. J. Pharmacol. Exp. Ther. 256:1991;890-896.
75. G.M. Schneider, D.T. Lysle, Effects of centrally administered opioid agonists on macrophage nitric oxide production and splenic lymphocyte proliferation, in: H. Friedman, T.K. Eisenstein, J.J. Madden, B.M. Sharp (Eds.), AIDS, Drugs of Abuse and the Neuroimmune Axis, Plenum, New York, 1996, pp. 81-88.
76. Selley D.E., Sim L.J., Xiao R., Liu Q., Childers S.R. μ-opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol. 51:1997;87-96.
77. Shavit Y., Depaulis A., Martin F.C., Terman G.W., Pechnick R.N., Zane C.J., Gale R.P., Liebeskind J.C. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc. Natl. Acad. Sci. U.S.A. 83:1986;7114-7117.
78. Shavit Y., Martin F.C., Yirmiya R., Ben-Eliyahu S., Terman G.W., Weiner H., Gale R.P., Liebeskind J.C. Effects of a single administration of morphine or footshock stress on natural killer cell cytotoxicity. Brain Behav. Immun. 1:1987;318-328.
79. Spanagel R., Herz A., Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55:1990;1734-1740.
80. Spanagel R., Herz A., Shippenberg T.S. Identification of the opioid receptor types mediating β-endorphin-induced alterations in dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 190:1990;177-184.
81. Takemori A.E., Portoghese P.S. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in β-funaltrexamine-treated mice. J. Pharmacol. Exp. Ther. 243:1987;91-94.
82. Tiseo P.J., Geller E.B., Adler M.W. Antinociceptive action of intracerebroventricularly administered dynorphin and other opioid peptides in the rat. J. Pharmacol. Exp. Ther. 246:1988;449-453.
83. Tortella F.C., Robles L., Mosberg H.I. Evidence for mu opioid receptor mediation of enkephalin-induced electroencephalographic seizures. J. Pharmacol. Exp. Ther. 240:1987;571-577.
84. Tseng L.F., Collins K.A. Different mechanisms mediating tail-flick inhibition induced by β-endorphin, DAMGO and morphine from ROb and GiA in anesthetized rats. J. Pharmacol. Exp. Ther. 257:1991;530-538.
85. Weber R.J., Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science. 245:1989;188-190.
86. 3H]naltrindole binding to delta opioid receptors in rat brain. Life Sci. 50:1992;PL119-PL124.